| HOME >> MEDICINE >> TECHNOLOGY |
Injection II-64
Biomet Acquires Cytosol Laboratories II-64
Portola Inks $470 M Agreement with Merck for Phase II
Anticoagulant II-64
Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma II-65
Nuvelo and ARCA biopharma Merge II-65
12. FOCUS ON SELECT GLOBAL PLAYERS II-66
Bayer Healthcare AG (Germany) II-66
Boehringer Ingelheim (Germany) II-66
Bristol-Myers Squibb Company (USA) II-66
Eisai Inc. (USA) II-67
GlaxoSmithKline plc (UK) II-67
LEO Pharmaceutical Products (Denmark) II-67
Mitsubishi Tanabe Pharma Corporation (Japan) II-68
Pfizer Inc. (USA) II-68
Sanofi (France) II-68
Teva Pharmaceutical Industries Ltd (Israel) II-69
Teva Pharmaceuticals USA (USA) II-69
13. GLOBAL MARKET PERSPECTIVE II-70
Table 4: World Recent Past, Current & Future Analysis for
Anticoagulants by Geographic Region/Country - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) II-70
Table 5: World Historic Review for Anticoagulants by
Geographic Region/Country - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) II-71
Table 6: World 15-Year Perspective for Anticoagulants by
Geographic Region/Country - Percentage Breakdown of Dollar
Sales for US, Japan, Europe, and Rest of World Markets for
Years 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-72
Table 7: World Recent Past, Current & Future Analysis for Oral
Anticoagulants by Geographic Region/Country - US, Japan,
Europ
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |